Acute Myeloid Leukemia
The importance of CD47 in MDS and other targets of interest
CD47 is a cell surface protein which is overexpressed in several cancer cells and appears to play an important role…
Date: 17th January 2023
Highlights in MDS at ASH 2022: treating lower-risk & higher-risk disease, trial updates, & more
The 64th American Society of Hematology (ASH) Annual Meeting and Exposition took place on December 10-13, 2022, in New Orleans,…
Date: 21st December 2022
iwAL 2022 Session V: mechanisms of resistance to targeted therapies in AML
The 4th International Workshop on Acute Leukemias (iwAL) 2022 took place in Nice, France, and brought together leading experts in the…
Date: 6th December 2022
iwAL 2022 Session III: novel targets, combinations and treatment strategies in AML
The 4th International Workshop on Acute Leukemias (iwAL) 2022 took place in Nice, France, and brought together leading experts in the…
Date: 16th November 2022
iwAL 2022 Session I: the standard of care in AML in 2022
The 4th International Workshop on Acute Leukemias (iwAL) 2022 took place in Nice, France, and brought together leading experts in…
Date: 28th October 2022
CAR-T therapy in AML: challenges and future outlooks
Acute myeloid leukemia (AML) is an aggressive and heterogeneous hematological malignancy that poses many challenges for diagnosis and treatment. While…
Date: 10th August 2022
ASH 2021: updates in FLT3 mutated AML
FMS-like tyrosine kinase 3 (FLT3) mutations are common in patients with acute myeloid leukemia (AML), and is often associated with…
Date: 11th February 2022
COSTEM: maintenance therapies for FLT3+ AML
The FMS-like tyrosine kinase 3 (FLT3) gene is mutated in approximately 30% of patients with acute myeloid leukemia (AML) and…
Date: 25th October 2021
EHA 2021: updates on novel agents for AML
A significant number of patients with acute myeloid leukemia (AML) are unable to withstand intensive chemotherapy regimens due to older…
Date: 8th September 2021
The AML Sessions: Highlights from ASCO/EHA 2021
Acute myeloid leukemia (AML) is a clonal hematologic malignancy defined by genetic heterogeneity due to recurrent gene mutations. Precision medicine…
Date: 7th July 2021
Key updates on CAR-T & cellular therapy for AML
Acute myeloid leukemia (AML) is the most common type of leukemia in adults and is highly heterogenous. AML is typically…
Date: 17th May 2021
The MDS Sessions: highlights from ASH 2020
Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid disorders characterized by the accumulation of dysplastic cells within the bone…
Date: 27th April 2021
